ArticleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2022
Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine.
Article in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.BMC geriatrics · 2024Pooled it
- Human primary antibody response to vaccination follows a partially sequential class-switching program with a checkpoint at IGHG2.Cell reports. Medicine · 2026Article
- CoronaVac-induced antibodies that facilitate Fc-mediated neutrophil phagocytosis track with COVID-19 disease resolution.Emerging microbes & infections · 2025Article
- Astragalus polysaccharide and aluminum adjuvant synergize to amplify immune responses induced by a recombinant COVID-19 vaccine.Human vaccines & immunotherapeutics · 2025Article
- Impaired antibody responses to heterologous ChAdOx1 nCoV-19 and BNT162b2 vaccination in individuals with type 2 diabetes.Scientific reports · 2025Article
- Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses Between Infection and Vaccination: Challenges for Epidemiological Research.The Journal of infectious diseases · 2025Article
- A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting.Scientific reports · 2025Article
- Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study.BMC infectious diseases · 2025Article
- In-depth immunochemical characterization of the serum antibody response using a dual-titration microspot assay.Frontiers in immunology · 2025Article
- Immune memory reactivation and T cell dynamics following 12-month homologous CoronaVac booster: a longitudinal cohort study.Frontiers in immunology · 2025Article
- Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months.Frontiers in medicine · 2025Article
- Dynamic SARS-CoV-2-specific B-cell and T-cell responses induced in people living with HIV after a full course of inactivated SARS-CoV-2 vaccine.Frontiers in immunology · 2025Article
- Article
- Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh.Scientific reports · 2024Article
- Article
- Intradermal Fractional ChAdOx1 nCoV-19 Booster Vaccine Induces Memory T Cells: A Follow-Up Study.Vaccines · 2024Article
- Longevity of antibody responses is associated with distinct antigen-specific B cell subsets early after infection.Frontiers in immunology · 2024Article
- SARS-CoV-2 spike-specific TSignal transduction and targeted therapy · 2023Article
- Longitudinal proteomic investigation of COVID-19 vaccination.Protein & cell · 2023Article
- B Cell Subtypes in Individuals Received mRNA or Inactivated Vaccine Boosters After Fully Vaccinated with CoronaVac: A Longitudinal Study.Infectious diseases & clinical microbiology · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe dynamic adaptive immune responses elicited by the inactivated virus vaccine CoronaVac remain elusive.
methodsIn a prospective cohort of 100 healthcare professionals naïve for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received two doses of CoronaVac, we analysed SARS-CoV-2-specific humoral and cellular responses at four different timepoints, including before vaccination (T1), 2 weeks after the first dose (T2), 2 weeks after the booster dose (T3), and 8-10 weeks after the booster dose (T4). SARS-CoV-2-specific antibodies, serum neutralizing activities, peripheral B cells, CD4
resultsSARS-CoV-2 spike-specific IgG responses reached a peak (geometric mean titre (GMT) 54827, 30969-97065) after two doses and rapidly declined (GMT 502, 212-1190) at T4, whereas suboptimal IgA responses were detected (GMT 5, 2-9). Spike-specific circulating B cells (0.60%, 0.46-0.73% of total B cells) and memory B cells (1.18%, 0.92-1.44% of total memory B cells) were effectively induced at T3 and sustained over time (0.33%, 0.23-0.43%; 0.87%, 0.05-1.67%, respectively). SARS-CoV-2-specific circulating CD4
conclusionsCoronaVac induced robust circulating and memory B cell and T cell responses. Our study offers new insight into the underlying immunobiology of inactivated virus vaccines in humans and may have implications for vaccine strategies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.